UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

 

Date of Report (Date of earliest event reported): March 14, 2013

 

 

BIOANALYTICAL SYSTEMS, INC.
(Exact name of registrant as specified in its charter)

 

Indiana   0-23357   35-1345024
(State or other jurisdiction of incorporation or organization)   (Commission File Number)   (I.R.S. Employer Identification No.)

 

 

2701 KENT AVENUE

WEST LAFAYETTE, INDIANA

  

 

47906-1382

(Address of principal executive offices)   (Zip Code)

 

Registrant's telephone number, including area code: (765) 463-4527

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act(17CFR240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act(17CFR240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act(17CFR240.13e-4(c))

 

 
 

Item 5.07. Submission of Matters to a Vote of Security Holders

 

On March 14, 2013, Bioanalytical Systems Inc. (the “Company”) held its annual meeting of shareholders at its corporate offices located at 2701 Kent Avenue, West Lafayette, IN 47906. A total of 5,638,186 shares of the Company’s common stock outstanding and entitled to vote were present at the meeting in person or by proxy. The following is a summary of the matters voted on at the meeting.

 

a.)Two Class I members of the Board of Directors were elected to serve three-year terms ending in 2016 with the following votes cast:

 

 

Nominee   For   Withheld   Broker Non-Vote
             
Larry S. Boulet                     3,085,183                        193,096                     2,359,907
             
A. Charlene Sullivan, Ph.D.                     3,028,707                        249,572                     2,359,907

 

 

b.)The appointment of Crowe Horwath LLP as our independent registered public accountants for fiscal 2013 was ratified by the following shareholder vote:

 

For:               3,963,099
     
Against:               1,575,634
     
Abstain:                    99,453

 

 

c.)By the following vote, the shareholders approved an advisory vote on compensation paid to named executive officers:

 

For:            3,025,362
     
Against:               184,042
     
Abstain:                 68,875
     
Broker Non-Vote:          2,359,907

 

 

d.)By the following vote, the shareholders voted, on an advisory basis, to hold future advisory votes on executive compensation every three years:

 

Annually:               694,770
     
Every 2 years:                 45,754
     
Every 3 years:            2,447,095
     
Abstain:                 90,660
     
Broker Non-Vote:            2,359,907

  

 
 

 

 

SIGNATURES

 

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

     
  Bioanalytical Systems, Inc.
     
Date: March 18, 2013 By:   /s/ Jacqueline M. Lemke
 

Jacqueline M. Lemke

  President, Chief Executive Officer